【摘要】：目的觀察芪藶強心膠囊輔治慢性心力衰竭(CHF)患者的療效及對N-末端腦鈉肽前體(NT-proBNP)、左室射血分數(shù)(LVEF)及Tei指數(shù)的影響。方法選擇2015年2月—2016年2月湖北省襄陽市東風人民醫(yī)院急診科診治CHF患者121例作為研究對象,隨機分為對照組60例及治療組61例。對照組患者進行標準抗心力衰竭治療,治療組患者在此基礎(chǔ)上加用芪藶強心膠囊,療程均12周。分別于初次入院、治療4周、8周及12周時測定NTproBNP、LVEF、Tei指數(shù)、LVEDD以及SV,治療結(jié)束后觀察療效,比較2組不良反應發(fā)生率。結(jié)果治療組總有效率為91.1%,顯著高于對照組的70.0%(x~2=7.662,P=0.006)。與治療前比較,2組患者治療后NT-proBNP、Tei指數(shù)、LVEDD顯著降低(對照組:F=9.324、5.830、3.622;治療組:F=12.305、6.207、5.637,P均0.05),LVEF及SV水平顯著升高(對照組:F=6.237、6.842;治療組:F=9.287、9.351,P均0.05),治療后12周,觀察組較對照組改善更加明顯,差異均具有統(tǒng)計學意義(t=8.483、6.344、6.118、14.829、8.878,P均0.05)。治療組出現(xiàn)輕微不良反應3例(5.4%),未出現(xiàn)嚴重不良反應。結(jié)論芪藶強心膠囊可有效改善患者心功能,安全性高,值得推廣使用。
[Abstract]:Objective to observe the efficacy of Qiliqiangxin capsule in the treatment of patients with chronic heart failure (CHF) and its effects on N- terminal brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF) and Tei index. Methods from February 2015 to February 2016, 121 patients with CHF were randomly divided into control group (n = 60) and treatment group (n = 61). The patients in the control group were treated with standard anti-heart failure, and the patients in the treatment group were treated with Qiliqiangxin capsule for 12 weeks. The NTproBNP,LVEF,Tei index and the efficacy of SV, were measured at the first admission, 4 weeks, 8 weeks and 12 weeks, respectively. The incidence of adverse reactions was compared between the two groups. Results the total effective rate of the treatment group was 91.1%, which was significantly higher than that of the control group (70.0%). Compared with those before and after treatment, the NT-proBNP,Tei index of the two groups was significantly lower than that of the control group (control group: 9. 3245.830v 3.622; the treatment group: 12. 3056.2075.637; P 0.05). The levels of NT-proBNP,Tei and SV were significantly increased (control group: F: 6.2376.842; treatment group: F9. 2879.351g, P 0.05). 12 weeks after treatment, the observation group improved more obviously than the control group. The difference was statistically significant (t = 8.483 ~ 6.344 ~ 6.118N = 14.829 ~ 8.878, P = 0.05). In the treatment group, there were 3 cases (5.4%) with slight adverse reactions, but no serious side effects. Conclusion Qiliqiangxin capsule can effectively improve cardiac function of patients with high safety and worth popularizing.
【作者單位】： 武漢大學基礎(chǔ)醫(yī)學院;湖北省襄陽市東風人民醫(yī)院急診科;
【分類號】：R259

【相似文獻】

相關(guān)期刊論文 前10條

1 薛立新;馮莉;;芪藶強心膠囊治療慢性充血性心力衰竭40例[J];中西醫(yī)結(jié)合心腦血管病雜志;2008年05期

2 丁梅;楊萍;何敏;馮朝暉;;芪藶強心膠囊治療慢性充血性心力衰竭效果評價[J];吉林大學學報(醫(yī)學版);2009年06期

3 高建步;李玉東;楊守忠;;芪藶強心膠囊治療慢性充血性心力衰竭[J];中國實驗方劑學雜志;2011年07期

4 王劍;;芪藶強心膠囊治療慢性充血性心力衰竭80例療效觀察[J];中國社區(qū)醫(yī)師;2011年47期

5 牛連英;張麗娜;趙曉靜;;芪藶強心膠囊對老年慢性收縮性心力衰竭療效及血清BNP水平的影響[J];疑難病雜志;2012年10期

6 盧統(tǒng)慶;李艷;趙瑩;馮思建;莊如意;;芪藶強心膠囊輔助治療老年慢性心力衰竭的臨床研究[J];現(xiàn)代生物醫(yī)學進展;2013年23期

7 路鳳月;王殿華;馮書文;;芪藶強心膠囊治療慢性充血性心力衰竭40例臨床觀察[J];浙江中醫(yī)雜志;2006年10期

8 黃顯南;黃照河;譚志輝;潘征;潘興壽;;芪藶強心膠囊治療慢性收縮性心力衰竭42例臨床觀察[J];疑難病雜志;2007年09期

9 蘇慧敏;;芪藶強心膠囊對慢性充血性心力衰竭病人生活質(zhì)量的影響[J];中西醫(yī)結(jié)合心腦血管病雜志;2007年10期

10 楊帆;賴沙毅;;芪藶強心膠囊治療慢性心力衰竭68例[J];中國中西醫(yī)結(jié)合雜志;2007年11期

相關(guān)會議論文 前10條

1 姚麗;李永星;劉麗娜;王琰;胡亞民;;芪藶強心膠囊治療慢性心力衰竭49例療效觀察[A];首屆中西醫(yī)血管病學大會論文匯編[C];2013年

2 劉春香;毛靜遠;王賢良;侯雅竹;張川;;芪藶強心膠囊治療慢性心力衰竭的系統(tǒng)評價[A];中華中醫(yī)藥學會心病分會第十一屆學術(shù)年會論文精選[C];2009年

3 王立新;趙宇;李富軍;何曉雷;王建斌;;芪藶強心膠囊治療難治性心力衰竭的臨床觀察[A];首屆中西醫(yī)血管病學大會論文匯編[C];2013年

4 錢玉紅;李爭;魏國清;劉穎;劉靜濤;史俊玲;黃U，

本文編號：2255119